Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test could spot hidden cancers before symptoms start

NCT ID NCT05155605

Diagnosis Sponsor: GRAIL, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new blood test that can detect many types of cancer early, even before symptoms appear. About 35,000 adults aged 50 and older will take the test, and if it finds a possible cancer signal, they will get follow-up exams to confirm. The goal is to see how well the test works and whether it helps find cancers early without causing unnecessary worry or procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

35,883 people

The number who actually took part.

Started

Dec 2021

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants must be at least 50 years of age, inclusive, at the time of signing the Informed Consent Form (ICF). 2. Participants must be capable of giving signed and legally effective informed consent Exclusion Criteria: 1. Undergoing or referred for diagnostic evaluation due to clinical suspicion for cancer (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality). 2. Personal history of invasive solid tumor or hematologic malignancy, diagnosed within the 3 years prior to expected enrollment date, or diagnosed greater than 3 years prior to expected enrollment date and never treated. * Individuals with a diagnosis of non-metastatic basal cell carcinoma and squamous cell carcinoma of the skin are not excluded. 3. Prior/Concurrent Concomitant Therapy (Medications/Treatments): * Definitive treatment for invasive solid tumor or hematologic malignancy within the 3 years prior to expected enrollment date. Adjuvant hormone therapy for cancer (e.g. for breast or prostate cancer) is not an exclusion criterion. 4. Individuals who will not be able to comply with the protocol procedures. 5. Individuals who are not currently registered patients at a participating center. 6. Previous or current participation in another GRAIL-sponsored study. "Participation" is defined as having signed consent and provided a blood sample. 7. Previous or current employees or contractors of GRAIL. 8. Current pregnancy (by self-report of pregnancy status)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Early detection of cancer

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Duke University Health System

    Durham, North Carolina, 27705, United States

  • Eastern Virginia Medical School

    Norfolk, Virginia, 23510, United States

  • Flushing Hospital Medical Center

    Queens, New York, 11355, United States

  • HOAG Irvine

    Irvine, California, 92663, United States

  • HOAG Newport Beach

    Newport Beach, California, 92663, United States

  • HOAG Vivante Newport Mesa

    Irvine, California, 92663, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Henry Ford Macomb

    Clinton, Michigan, 48038, United States

  • Henry Ford Medical Center Detroit North West

    Detroit, Michigan, 48235, United States

  • Henry Ford Medical Center Ford Road

    Dearborn, Michigan, 48126, United States

  • Henry Ford Medical Center Harbortown

    Detroit, Michigan, 48207, United States

  • Henry Ford Medical Center Sterling Heights

    Sterling Heights, Michigan, 48310, United States

  • Inova

    Fairfax, Virginia, 22031, United States

  • Jamaica Hospital Medical Center

    Queens, New York, 11418, United States

  • Kelsey-Seybold Clinic Cypress Woods

    Houston, Texas, 77014, United States

  • Kelsey-Seybold Clinic Holcombe

    Houston, Texas, 77025, United States

  • Long Beach Memorial Medical Center

    Long Beach, California, 90806, United States

  • Maryland Oncology Hematology

    Annapolis, Maryland, 21401, United States

  • Mayo Clinic - Cancer Center

    Rochester, Minnesota, 55905, United States

  • Medstar Washington Hospital Center

    Northwest, District of Columbia, 20010, United States

  • Morehouse School of Medicine

    Atlanta, Georgia, 30310, United States

  • Northwest Cancer Specialists

    Vancouver, Washington, 98684, United States

  • Ochsner Grove

    Baton Rouge, Louisiana, 70836, United States

  • Ochsner Health

    New Orleans, Louisiana, 70127, United States

  • Ochsner Lafayette General

    Lafayette, Louisiana, 70503, United States

  • Oregon Health & Science University Bay Area Hospital

    Coos Bay, Oregon, 97420, United States

  • Oregon Health & Science University Knight Cancer Institute

    Portland, Oregon, 97201, United States

  • PAMF - Santa Cruz

    Santa Cruz, California, 95062, United States

  • PAMF - Sunnyvale

    Sunnyvale, California, 94086, United States

  • Palo Alto Medical Foundation

    Palo Alto, California, 94301, United States

  • SALEM Health

    Salem, Oregon, 97301, United States

  • Sarah Cannon Asheville Family Medicine

    Asheville, North Carolina, 28801, United States

  • Sarah Cannon Research Institute - Englewood Primary Care

    Englewood, Colorado, 80113, United States

  • Sarah Cannon Research Institute - The Frist Clinic

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon, Austin Diagnostic Clinic

    Austin, Texas, 78758, United States

  • Sarah Cannon, Centennial Internal Medicine Continuity Clinic

    Nashville, Tennessee, 37203, United States

  • St. Charles Health System

    Bend, Oregon, 97701, United States

  • Sutter Health

    Auburn, California, 95602, United States

  • Sutter Health

    Davis, California, 95616, United States

  • Sutter Health

    Elk Grove, California, 95758, United States

  • Sutter Health

    Fairfield, California, 94534, United States

  • Sutter Health

    Modesto, California, 95355, United States

  • Sutter Health

    Sacramento, California, 95816, United States

  • Texas Oncology - Plano East

    Plano, Texas, 75075, United States

  • Texas Oncology - Plano West

    Plano, Texas, 75093, United States

  • Texas Oncology - Tyler

    Tyler, Texas, 75702, United States

  • Texas Oncology - West Texas

    Amarillo, Texas, 79106, United States

  • University Health Network

    Toronto, Ontario, M5G 2C1, Canada

  • University Texas Health San Antonio - Mays Cancer Center

    San Antonio, Texas, 78229, United States

  • University of Illinois at Chicago

    Chicago, Illinois, 60608, United States

  • University of Oklahoma

    Oklahoma City, Oklahoma, 73104, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23219, United States

  • Weill Cornell Medicine

    New York, New York, 10065, United States

  • Woodlands Medical Specialists

    Pensacola, Florida, 32503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.